We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,231

Sandoz v Amgen: An update
  • Bristows
  • USA
  • January 9 2018

In our most recent publication, the Bristows' Biotech Review (Page 3), we reported on the US Supreme Court decision which, at the time, was the latest

What Could Happen to Imports If Government Shuts Down: 2017 Version
  • Arent Fox LLP
  • USA
  • December 15 2017

Based on recent activity in Congress, the possibility of a shutdown of US federal government activities for at least a brief period of time is looming

Congressional Hearings Focus on Health Policy Issues
  • Reed Smith LLP
  • USA
  • November 29 2017

A number of Congressional panels have scheduled or held recent hearings on health policy issues, including the following

Washington Healthcare Update - Sep 25, 2017
  • McGuireWoods LLP
  • USA
  • September 25 2017

On Sept. 20, the Congressional Diabetes Caucus Chairs Reps. Diana DeGette (D-CO) and Tom Reed (R-NY) sent a letter to FDA Commissioner Scott Gottlieb

U.S. Congress Reauthorizes Food and Drug Administration User Fee Programs, Acts on Other FDA Measures
  • Sidley Austin LLP
  • USA
  • August 15 2017

After more than two years of negotiations and just before the summer recess, the Senate voted to reauthorize the Food and Drug Administration's (FDA

The Congressional Agenda for August
  • Covington & Burling LLP
  • USA
  • August 1 2017

A brief column for a brief work period. The House left at the end of last week for its annual August break. The Senate had been scheduled to join the

Members of Congress Call for Review of FDA Guidance on Compounding under Section 503A
  • FisherBroyles LLP
  • USA
  • June 28 2017

Earlier this year, we focused one of our client alerts on a new Guidance issued by the Food and Drug Administration (FDA) concerning certain

Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • June 26 2017

Senate Republican leaders are expected to make a series of changes to the healthcare legislation released Thursday as they scramble to gain the

Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • June 19 2017

With only 10 legislative days before Senate Republicans’ self-imposed deadline, GOP lawmakers face growing obstacles in their quest to vote on

Metallizing Forfeiture Post-Helsinn
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • June 13 2017

In Helsinn Healthcare S.A. V. Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the